Breast cancer remains a leading cause of cancer-related deaths in women worldwide. To effectively combat this disease, a more concerted effort is necessary. The adoption of a combinatorial approach, leveraging various targeted therapies, has emerged as a promising path forward. In a recent pre-clinical collaborative study involving Louisiana State University, University of Rochester and CellestiaBiotech AG, the team has demonstrated the potential of CB-103, when combined with CDK4/6 inhibitors and Fulvestrant, to treat ESR1 mutated ER+ breast cancer. Moreover, the combination of CB-103 with paclitaxel has shown promise as a maintenance therapy for treating triple-negative breast cancer.